Reading the tape
NYSE: HAE
Haemonetics Corporation
Healthcare · Medical - Instruments & Supplies
Market Cap
$2.58B
52w High
$87.32
52w Low
$47.32
P/E
14.83
Volume
428.49K
Outstanding Shares
46.47M
Valuation Data Insufficient
The DCF model's fair value estimate is more than 3× the current stock price. This typically indicates unreliable model inputs — such as irregular cash flows or balance sheet distortions — rather than a genuine opportunity, so the valuation is not shown.
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: -10.93%Revenue (TTM): -4.02%FCF (TTM): 221.15%P/FCF: 0th pct
What changed
The stock fell 10.93% over the last year. Revenue declined 4.02% over the trailing twelve months. Operating margin moved from 13.14% to 19.21%. Free cash flow grew 221.15% over the trailing twelve months.
What the market seems to be pricing
The stock has moved lower against modestly improving underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at 19.21%. A decisive move in revenue — currently down 4.02% — would be the clearest signal to resolve the ambiguity.
Company profile
Haemonetics Corporation, a healthcare company, provides medical products and solutions.
CEOChristopher A. Simon
SectorHealthcare
IndustryMedical - Instruments & Supplies
Employees3,657
IPO dateMay 10, 1991
Valuation
Forward P/E—
EV/EBITDA11.51
Enterprise value$4.1B
Stock splits
Dec 3, 2012↑ Forward
Every 1 shares became 2
Jan 11, 1993↑ Forward
Every 1 shares became 2
Profitability & growth
Revenue growth-2.75%
Gross margin58.49%▲5.20%vs FY2024
Operating margin19.21%▲29.41%vs FY2024
ROE20.43%▲66.81%vs FY2024
Analyst consensus
RatingBuy
Target price$84.60▲52.10%
10
Buy
10
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 7, 2026
Q2 FY26 · EPS est $1.28 · Revenue est $336.86M
View